tiprankstipranks
Trending News
More News >
Softmax Co., Ltd. (Japan) (JP:3671)
:3671
Japanese Market

Softmax Co., Ltd. (Japan) (3671) AI Stock Analysis

Compare
1 Followers

Top Page

JP:3671

Softmax Co., Ltd. (Japan)

(3671)

Select Model
Select Model
Select Model
Neutral 62 (OpenAI - 5.2)
Rating:62Neutral
Price Target:
¥355.00
▲(6.29% Upside)
Action:ReiteratedDate:02/18/26
The score is driven primarily by weakening financial trends in 2025 (revenue decline, margin pressure, softer operating cash flow, and higher leverage), partially offset by a reasonable valuation (P/E ~14) and dividend yield (~3%). Technical signals are neutral-to-weak, reinforcing near-term caution.
Positive Factors
Stable profitability margins
Consistent net margins near 8–9% and EBIT in the low-teens across multiple years indicate a resilient profit model and structural cost controls. This durability supports predictable earnings and earnings quality, helping the business absorb cyclical volatility over the next 2–6 months.
High free cash flow conversion
Very strong FCF conversion versus net income shows reported profits translate into cash, supporting dividends, any necessary capex, and potential debt paydown. Reliable cash generation strengthens financial flexibility and resilience to medium-term shocks.
Historically healthy ROE and scale growth
Mid-teens ROE and expanding asset/equity base reflect effective capital allocation and business scale. Persistent above-average returns suggest sustainable competitive advantages or operational efficiency that support medium-term profitability and reinvestment capacity.
Negative Factors
Sharp 2025 revenue decline
A 22% revenue drop in the most recent year signals meaningful demand or contract loss that can structurally impair growth momentum. If persistent, revenue contraction pressures operating leverage, investment plans, and the company’s ability to maintain prior margin and cash generation levels.
Rising financial leverage
A material step-up in leverage reduces financial flexibility and raises interest exposure, limiting room to maneuver if revenues or margins remain weak. Higher debt amplifies downside risk and could force tighter capital allocation over the medium term.
Deteriorating operating cash flow
A sharp fall in operating cash flow reduces internal funding capacity and increases reliance on external financing. Lower OCF relative to revenue undermines the strong FCF conversion story if the trend continues, constraining dividends, capex, and debt reduction plans.

Softmax Co., Ltd. (Japan) (3671) vs. iShares MSCI Japan ETF (EWJ)

Softmax Co., Ltd. (Japan) Business Overview & Revenue Model

Company DescriptionSoftmax Co., Ltd develops, sales, introduction, and maintenance of corporate systems. It is also involved in medical information system development. The company also offers web based electronic medical record system, web based ordering system, medical accounting, radiology information, rehabilitation department system, health check-up system, nursing work management system, and surgical department system. Softmax Co., Ltd was incorporated in 1974 and is headquartered in Tokyo, Japan.
How the Company Makes MoneySoftmax Co., Ltd. generates revenue through multiple streams, primarily from software licensing, subscription models, and consulting services. The company earns money by selling licenses for its proprietary software solutions, which are used by businesses to improve their operational efficiency. Additionally, Softmax offers subscription-based services for its cloud-based applications, providing customers with ongoing access to updates and support. Consulting services also contribute significantly to its revenue, as the company assists clients in integrating and customizing software solutions to meet their specific needs. Strategic partnerships with other technology firms and collaborations with industry leaders further enhance its market reach and create additional revenue opportunities.

Softmax Co., Ltd. (Japan) Financial Statement Overview

Summary
Profitable with generally steady historical margins and good free cash flow conversion versus earnings, but 2025 showed a sharp 22% revenue decline, margin compression, weaker operating cash flow, and higher leverage (debt-to-equity rising to ~0.63).
Income Statement
66
Positive
Profitability is solid and fairly steady, with net margins staying in the ~8–9% range from 2020–2025 and EBIT margin generally in the low-teens. However, the growth profile weakened materially in the latest year: revenue declined 22% in 2025 (annual) after modest growth in 2023–2024, and margins also compressed (gross margin fell to ~26.9% in 2025 from ~30.8% in 2024). Overall, the company remains profitable, but the sharp 2025 revenue drop and margin pressure weigh on the score.
Balance Sheet
63
Positive
The balance sheet shows moderate leverage and improving scale (assets and equity have grown over time), but debt has risen notably in the most recent year. Debt-to-equity increased to ~0.63 in 2025 (annual) from ~0.40–0.46 in 2022–2024, indicating a higher reliance on borrowing. Returns on equity were healthy in 2021–2024 (mid-teens), supporting underlying business quality, but the step-up in leverage adds financial risk if earnings volatility persists.
Cash Flow
55
Neutral
Cash conversion is mixed. Free cash flow tracks net income well (free cash flow is ~91–99% of net income across 2021–2025), which is a positive indicator of earnings quality. The key weakness is low operating cash flow relative to revenue (roughly mid-single digits in recent years) and a deterioration in 2025, when operating cash flow fell to 389M from 663M in 2024 and represented a smaller share of net income than in 2024. Cash generation is positive, but consistency and operating cash flow strength are the main watch items.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.94B6.93B5.43B5.26B5.05B4.49B
Gross Profit1.88B1.86B1.67B1.57B1.44B1.45B
EBITDA962.17M784.12M745.36M658.89M624.09M652.10M
Net Income646.45M573.46M480.15M452.00M419.39M422.55M
Balance Sheet
Total Assets7.04B9.13B7.54B6.72B6.55B5.76B
Cash, Cash Equivalents and Short-Term Investments3.11B3.12B3.45B2.92B2.85B2.76B
Total Debt1.00B2.48B1.41B1.33B1.35B1.38B
Total Liabilities3.38B5.20B4.02B3.50B3.61B3.14B
Stockholders Equity3.65B3.93B3.52B3.22B2.94B2.62B
Cash Flow
Free Cash Flow0.00384.89M624.00M215.00M163.80M259.73M
Operating Cash Flow0.00388.95M663.00M232.00M179.73M284.30M
Investing Cash Flow0.00-1.17B-92.76M-11.00M-4.75M-1.01M
Financing Cash Flow0.00883.56M-100.22M-200.04M-144.93M-401.85M

Softmax Co., Ltd. (Japan) Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price334.00
Price Trends
50DMA
342.56
Negative
100DMA
346.88
Negative
200DMA
321.12
Positive
Market Momentum
MACD
-8.39
Positive
RSI
44.65
Neutral
STOCH
27.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3671, the sentiment is Neutral. The current price of 334 is above the 20-day moving average (MA) of 327.60, below the 50-day MA of 342.56, and above the 200-day MA of 321.12, indicating a neutral trend. The MACD of -8.39 indicates Positive momentum. The RSI at 44.65 is Neutral, neither overbought nor oversold. The STOCH value of 27.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3671.

Softmax Co., Ltd. (Japan) Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
¥11.22B29.025.30%0.09%-48.79%
63
Neutral
¥65.48B226.810.39%6.17%-8918.66%
63
Neutral
¥273.19B39.510.43%20.55%48.62%
62
Neutral
¥8.08B14.088.09%32.95%45.22%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
¥64.95B64.708.79%31.95%-40.95%
45
Neutral
¥3.02B-5.6016.19%-4.42%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3671
Softmax Co., Ltd. (Japan)
336.00
129.60
62.79%
JP:4480
Medley
1,984.00
-791.00
-28.50%
JP:3902
Medical Data Vision Co.Ltd.
1,679.00
1,273.00
313.55%
JP:4438
Welby Inc.
365.00
67.00
22.48%
JP:4483
JMDC Inc.
4,175.00
1,221.53
41.36%
JP:9341
GENOVA Inc.
629.00
-397.25
-38.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 18, 2026